Management of medication-overuse headache

Expert Review of Neurotherapeutics

Volumn 7, Issue 9, 2007, Pages 1145-1155

  Obermann, Mark ^a   Katsarava, Zaza ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Analgesics; Chronic headache; Chronic migraine; Ergot; Management; Medication overuse headache; Relative risk; Triptan

Indexed keywords

ANALGESIC AGENT; DIPYRONE; NARATRIPTAN; OPIATE; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

DISEASE CLASSIFICATION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; HUMAN; PREVALENCE; REVIEW; RISK FACTOR;

ANALGESICS; BARBITURATES; CHRONIC DISEASE; HEADACHE DISORDERS, SECONDARY; HUMANS; MIGRAINE DISORDERS;

EID: 34548821604     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.9.1145     Document Type: Review

References (91)

1. Peters GA, Horton BT. Headache with special reference to the excessive use of ergotamine preparations and withdrawal effects. Proc. Staff Meet. Mayo. Clin. 26, 153-161 (1951).
2. Horton BT, Peters GA. Clinical manifestations of excessive use of ergotamine preparations and management withdrawal effect-report of 52 cases. Headache 3, 214-226 (1963).
3. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8(Suppl. 7), 1-96 (1988).
4. International Headache Society. The International Classification of Headache Disorders. Cephalalgia 24, 1-160 (2004). •• This classification took 15 years to complete and will be the most important reference for the definition of all headache disorders for the years to come.
5. Silberstein SD, Olesen J, Bousser MG et al. The International Classification of Headache Disorders, (2nd Edition) - revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 25, 460-465 (2005).
6. Olesen J, Bousser MG, Diener HC et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26, 742-746 (2006). •• This paper introduced the novel broader concept of medication-overuse headache (MOH).
7. Diener HC, Dahlof CG. Headache associated with chronic use of substances. In: The Headaches (2nd Edition). Olesen J, Tfelt-Hansen P, Welch KM (Eds). Lippincott, Williams & Wilkins, Philadelphia, PA, USA 871-878 (1999).
8. Lance F, Parkes C, Wilkinson M. Does analgesic abuse cause headache de novo? Headache 38, 61-62 (1988).
9. Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular analgesic use? Headache 43, 179-190 (2003). • Interesting study that provides evidence for a genetic disposition to develop MOH.
10. Zwart JA, Dyb G, Hagen K et al. Analgesic use - a predictor of chronic pain and medication overuse headache-the Head-HUNT Study. Neurology 61, 160-164 (2003). •• Huge epidemiological study from Norway.
11. Katsarava Z, Schneeweiss S, Kurth T et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 62(5), 788-790 (2004). • One of the few prospective studies addressing the problem of chronification in patients with migraine.
12. Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 59, 1011-1014 (2002). •• Important research that correlates clinical features with pharmacological parameters and gives out the mean critical monthly dosages for different antiheadache drugs.
13. Meskunas CA, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache 46, 766-772 (2006).
14. Paemeleire K, Bahra A, Evers S, Matharu MS, Goadsby PJ. Medication-overuse headache in patients with cluster headache. Neurology 67, 109-113 (2006).
15. Reuter U, Salomone S, Ickstein GW, Waeber C. Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats. Cephalalgia 24, 398-407 (2004).
16. Saucier C, Morris SJ, Albert PR. Endogenous serotonin-2A and -2C receptors in Balb/c-3T3 cells revealed in serotonin-free medium-desensitisation and down-regulation by serotonin. Biochem. Pharmacol. 56, 1347-1357 (1998).
17. Tohyama Y, Yamane F, Fikre Merid M, Blier P, Diksic M. Effects of serotonin receptor agonists, TFMPP and CGS12066B, on regional serotonin synthesis in the rat brain - an autoradiographic study. J. Neurochem. 80, 788-798 (2002).
18. Dobson CF, Tohyama Y, Diksic M, Hamel E. Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain. Cephalalgia 24, 2-11 (2004). • One of the very few papers that investigated the effect of chronic triptan treatment experimentally.
19. Srikiatkhachorn A, Anthony M. Platelet serotonin in patients with analgesic-induced headache. Cephalalgia 16, 423-426 (1996).
20. Srikiatkhachorn A, Tarasub N, Govitrapong P. Effect of chronic analgesic exposure on the central serotonin system - a possible mechanism of analgesic abuse headache. Headache 40, 343-350 (2000).
21. Bendtsen L, Jensen R, Olesen J. Decreased pain detection and tolerance thresholds in chronic tension-type headache. Arch. Neurol. 53, 373-376 (1996).
22. De Tommaso M, Libro G, Guido M et al. Heat pain thresholds and cerebral eventrelated potentials following painful CO2 laser stimulation in chronic tension-type headache. Pain 104, 111-119 (2003).
23. Ayzenberg I, Obermann M, Nyhuis P et al. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia 26, 1106-1114 (2006).
24. Schmidt-Wilcke T, Leinisch E, Straube A et al. Gray matter decrease in patients with chronic tension type headache. Neurology 65, 1483-1486 (2005). •• Only imaging study showing morphological changes in patients with chronic tension-type headache.
25. Fumal A, Laureys S, Di Clemente L et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain 129, 543-550 (2006).
26. Griffiths RR, Woodson PP. Caffeine physical dependence - a review of human and laboratory animal studies. Psychopharmacology 94, 437-451 (1988).
27. Griffiths RR, Woodson PP. Reinforcing properties of caffeine-studies in humans and laboratory animals. Pharmacol. Biochem. Behav. 29, 419-427 (1988).
28. van Dusseldorp M, Katan MB. Headache caused by caffeine withdrawal among moderate coffee drinkers switched from ordinary to decaffeinated coffee-a 12 week double blind trial. Br. Med. J. 300, 1558-1559 (1990).
29. Silverman K, Evans SM, Strain EC, Griffiths RR. Withdrawal syndrome after the double-blind cessation of caffeine consumption. N. Engl. J. Med. 327, 1109-1114 (1992).
30. Scher AI, Stewart WF, Lipton RB. Caffeine as a risk factor for chronic daily headache - a population-based study. Neurology 63, 2022-2027 (2004). • Important study demonstrating that caffeine is a risk factor for headache chronicity.
31. Ziegler DK. Opiate and opioid use in patients with refractory headache. Cephalalgia 14, 5-10 (1994).
32. Fisher MA, Glass S. Butorphanol (Stadol) - a study in problems of current drug information and control. Neurology 48, 1156-1160 (1997).
33. Saper JR, Jones JM. Ergotamine tartrate dependency - features and possible mechanisms. Clin. Neuropharmacol. 9, 244-256 (1986).
34. Fanciullacci M, Alessandri M, Pietrini U, Briccolani-Bandini E, Beatrice S. Long-term ergotamine abuse-effect on adrenergically induced mydriasis. Clin. Pharm. Ther. 51, 302-307 (1992).
35. Ferrari A, Cicero AFG, Bertolini A, Leone S, Pasciullo G, Sternieri E. Need for analgesics/drugs of abuse - a comparison between headache patients and addicts by the Leeds Dependence Questionnaire (LDQ). Cephalalgia 26, 187-193 (2005).
36. Fuh J-L, Wang S-J, Lu S-R, Juang K-D. Does medication overuse headache represent a behavior of dependence? Pain 119, 49-55 (2005).
37. Castillo J, Munoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache 39, 190-196 (1999).
38. Colas R, Munoz P, Temprano R, Gomez C, Pascual J. Chronic daily headache with analgesic overuse - epidemiology and impact on quality of life. Neurology 27, 1338-1342 (2004).
39. Lanteri-Minet M, Auray JP, El Hasnaoui A. Prevalence and description of chronic daily headache in the general population of France. Pain 102, 143-149 (2003).
40. Lu SR, Fuh JL, Chen WT, Juang KD, Wang SJ. Chronic daily headache in Taipei, Taiwan-prevalence, follow-up and outcome predictors. Cephalalgia 21, 980-986 (2001).
41. Prencipe M, Casini AR, Ferretti C et al. Prevalence of headache in an elderly population-attack frequency, disability, and use of medication. J. Neurol. Neurosurg. Psychiatr. 70, 377-381 (2001).
42. Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache 38, 497-506 (1998).
43. Wang SJ, Fuh JL, Lu SR et al. Chronic daily headache in Chinese elderly - prevalence, risk factors, and biannual follow-up. Neurology 54, 314-319 (2000).
44. Wang SJ, Fuh JL, Lu SR, Juang KD. Chronic daily headache in adolescents. Prevalence, impact, and medication overuse. Neurology 66, 193-197 (2006).
45. Schwarz A, Farber U, Glaeske G. Daten zu Analgetikakonsum und Analgetikanephropathie in der Bundesrepublik. Offentl. Gesundheitswes. 47, 298 (1985).
46. Gutzwiller F, Zemp E. Der Analgetikakonsum in der Bevölkerung und sozioökonomische Aspekte des Analgetikaabusus. In: Das Analgetikasyndrom. Mihatsch MJ (Ed). Thieme, Stuttgart, Germany 197 (1986).
47. Eggen AE. The Tromsø study-frequency and predicting factors of analgesic drug use in a free living population (12-56 years). J. Clin. Epidemiol 46, 1297-1304 (1993).
48. Hering-Hanit R, Cohen A, Horev Z. Successful withdrawal from analgesic abuse in a group of youngsters with chronic daily headache. J. Child Neurol. 16, 448-449 (2001).
49. Symon DN. Twelve cases of analgesic headache. Arch. Dis. Child. 78, 555-556 (1998).
50. Robinson RG. Pain relief for headaches. Cam. Fam. Physician. 39, 867 (1993).
51. Granella F, Farina S, Malferrari G, Manzoni GC. Drug abuse in chronic headache - a clinico-epidemiologic study. Cephalalgia 7, 15-19 (1987).
52. Micieli G, Manzoni GC, Granella F, Martignoni E, Malferrari G, Nappi G. Clinical and epidemiological observations on drug abuse in headache patients. In: Drug-induced Headache. Diener HC, Wilkinson M (Eds). Springer, NY, USA 20-28 (1988).
53. Celentano DD, Stewart WF, Lipton RB et al. Medication use and disability among migraineurs - a national probability sample. Headache 32, 223-228 (1992).
54. Rapoport A, Weeks R, Sheftell F. Analgesic rebound headache - theoretical and practical implications. In: Proceedings Second International Headache Congress. Olesen J, Tfelt-Hansen P, Jensen K (Eds). Copenhagen, Denmark 448-449 (1985).
55. Baumgartner C, Wessely P, Bingol C, Maly J, Holzner F. Long-term prognosis of analgesic withdrawal in patients with drug-induced headaches. Headache 29, 510-514 (1989).
56. Mathew NT, Kurman R, Perez F. Drug induced refractory headache - clinical features and management. Headache 30, 634-638 (1990).
57. Catarci T, Fiacco F, Argentino C, Sette G, Cerbo R. Ergotamine-induced headache can be sustained by sumatriptan daily intake. Cephalalgia 14, 374-375 (1994).
58. Kaube H, May A, Diener HC, Pfaffenrath V. Sumatriptan misuse in daily chronic headache. Br. Med. J. 308, 1573-1574 (1994).
59. Williams D, Cahill T, Dowson A et al. Usage of triptans among migraine patients - an audit in nine GP practices. Curr. Med. Res. Opin.18, 1-9 (2002).
60. Gaist D, Andersen M, Aarup AL et al. Use of sumatriptan in Denmark in 1994-5-an epidemiological analysis of nationwide prescription data. Br. J. Clin. Pharmacol. 43, 429-433 (1997).
61. Gaist D, Tsiropoulus I, Sindrup SH et al. Inappropriate use of sumatriptanpopulation based register and interview study. Br. Med. J. 316, 1352-1353 (1998).
62. Gaist D, Hallas J, Sindrup SH, Gram LF. Is overuse of sumatriptan a problem? A population-based study. Eur. J. Clin. Pharmacol. 50, 161-165 (1996).
63. Lucas C, Auray JP, Gaudin AF et al. Use and misuse of triptans in France - data from the GRIM2000 population survey. Cephalalgia 24, 197-205 (2004).
64. Katsarava Z, Muessig M, Dzagniza A, Fritsche G, Diener HC, Limmroth V. Rate and predictors for relapses in medication overuse headache - a four year prospective study. Cephalalgia 25, 12-15 (2005).
65. Hagen K, Vatten L, Stovner LJ et al. Low socio-economic status is associated with increased risk of frequent headache - a prospective study of 22,718 adults in Norway. Cephalalgia 22, 672-679 (2002).
66. Zeeberg P, Olesen J, Jensen R. Efficacy of multidisciplinary treatment in a tertiary referral headache centre. Cephalalgia 25, 1159-1167 (2005).
67. Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients - recovery of therapeutic responsiveness. Cephalalgia 26, 1192-1198 (2006).
68. Relja G, Granato A, Bratina A, Antonello RM, Zorzon M. Outcome of medication overuse headache after abrupt in-patient withdrawal. Cephalalgia 26, 589-595 (2006).
69. Rossi P, Di Lorenzo C, Faroni J, Cesarino F, Nappi G. Advice alone vs. structured detoxification programmes for medication overuse headache - a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia 26, 1097-1105 (2006).
70. Krymchantowski AV, Barbosa JS. Prednisone as initial treatment of analgesicinduced daily headache. Cephalalgia 20, 107-113 (2000).
71. Smith TR. Low-dose tizanidine with nonsteroidal anti-inflammatory drugs for detoxification from analgesic rebound headache. Headache 42, 175-177 (2002).
72. Diener H-C, Haab J, Peters C et al. Subcutaneous sumatriptan in the treatment of headache during withdrawal from drug-induced headache. Headache 31, 205-209 (1990).
73. Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache. An open label study. Headache 31, 71-74 (1991).
74. Mei D, Ferraro D, Zelano G et al. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin. Neuropharmacol. 29, 269-275 (2006).
75. Haag G, Barr H, Grotemeyer KH, Pfaffenrath V, Ribbat MJ, Diener HC. Prophylaxis and treatment of drug-induced persistent headache. Therapy recommendation of the German Society for Migraine and Headache. Schmerz 13(1), 52-57 (1999).
76. Warner JS. The outcome of treating patients with suspected rebound headache. Headache 41, 685-692 (2001).
77. Hering R, Steiner TJ. Abrupt outpatient withdrawal of medication in analgesic-abusing migraineurs. Lancet 337, 1442-1443 (1991).
78. Haag G, Baar H, Grotemeyer KH et al. Prophylaxe und Therapie des Medikamenteninduzierten Dauerkopfschmerzes. Schmerz 13, 52-57 (1999).
79. Katsarava Z, Limmroth V, Finke M et al. Rate and predictors for relapses in medication overuse headache - a one year prospective study. Neurology 60, 1682-1684 (2003). • Provides new prospective data on relapse rates and predictors.
80. Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD; BOTOX CDH Study Group. Botulinum toxin type A for the prophylaxis of chronic daily headache-subgroup analysis of patients not receiving other prophylactic medications - a randomized double-blind, placebo-controlled study. Headache 45, 315-324 (2005).
81. Schulte-Mattler WJ, Krack P. BoNTTH Study Group. Treatment of chronic tension-type headache with botulinum toxin A - a randomized, double-blind, placebo-controlled multicenter study. Pain 109, 110-114 (2004).
82. Diener HC, Dichgans J, Scholz E, Geiselhart S, Gerber WD, Bille A. Analgesic-induced chronic headache - long-term results of withdrawal therapy. J. Neurol. 236, 9-14 (1989).
83. Schnider P, Aull S, Baumgartner C et al. Long-term outcome of patients with headache and drufg abuse after inpatient withdrawal - five year follow-up. Cephalalgia 16, 481-485 (1996).
84. Grazzi L, Andrasik F, D'Amico D et al. Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse - outcome at 3 years. Headache 42, 483-490 (2002).
85. Evers S, Suhr B, Bauer B, Grotemeyer KH, Husstedt IW. A retrospective long-term analysis of the epidemiology and features of drug-induced headache. J. Neurol. 246, 802-809 (1999).
86. Pini LA, Cicero AF, Sandrini M. Long-term follow-up of patients treated for chronic headache with analgesic overuse. Cephalalgia 21, 878-883 (2001).
87. Tribl GG, Schnider P, Wober C et al. Are there predictive factors for long-term outcome after withdrawal in drug-induced chronic daily headache? Cephalalgia 21, 691-696 (2001).
88. Fritsche G, Eberl A, Katsarava Z, Limmroth V, Diener HC. Drug-induced headache - long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur. Neurol. 45, 229-235 (2001).
89. Silberstein SD, Lipton RB, Dodick DW et al. Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine - a randomized, double-blind, placebo-controlled trial. Headache 47, 170-180 (2007).
90. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia 23, 820-824 (2003).
91. Bartolini M, Silvestrini M, Taffi R et al. Efficacy of topiramate and valproate in chronic migraine. Clin. Neuropharmacol. 28, 277-279 (2005).